Influenza hemagglutinin and neuraminidase variants
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
1. A reassortant influenza virus, wherein said virus comprises 6 internal genome segments from one or more donor viruses other than A/Ann Arbor/6/60 and a genome segment encoding an immunogenic influenza surface antigen comprising the amino acid sequence of SEQ ID NO: 11.
2. The reassortant influenza virus of claim 1 , wherein the 6 internal genome segments of the one or more donor viruses are selected for comprising one or more phenotypic attributes selected from the group consisting of: attenuated, cold adapted and temperature sensitive.
3. The reassortant influenza virus of claim 1 , wherein said one or more donor viruses are PR8.
4. The reassortant influenza virus of claim 1 , wherein said one or more donor viruses are A/Leningrad/17.
5. An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of claim 1 .
6. An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of claim 2 .
7. An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of claim 3 .
8. An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of claim 4 .
9. A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of claim 1 in a physiologically effective carrier.
10. A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of claim 2 in a physiologically effective carrier.
11. A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of claim 3 in a physiologically effective carrier.
12. A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of claim 4 in a physiologically effective carrier.
13. A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, the virus of claim 1 in an amount effective to produce an immunogenic response against the viral infection.
14. A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, the virus of claim 3 in an amount effective to produce an immunogenic response against the viral infection.
15. A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, the virus of claim 4 in an amount effective to produce an immunogenic response against the viral infection.
16. The method of claim 13 , wherein said virus is killed or inactivated.
17. The method of claim 14 , wherein said virus is killed or inactivated.
18. The method of claim 15 , wherein said virus is killed or inactivated.
19. The method of claim 9 , wherein the subject is a human.
20. The method of claim 10 , wherein the subject is a human.
21. The method of claim 11 , wherein the subject is a human.
22. A live attenuated influenza vaccine comprising the composition of claim 5 .
23. A live attenuated influenza vaccine comprising the composition of claim 6 .
24. A split virus or killed virus vaccine comprising the immunogenic composition of claim 5 .
25. A split virus or killed virus vaccine comprising the immunogenic composition of claim 6 .
26. A method for producing influenza viruses in cell culture, the method comprising:
i) introducing into a population of host cells a plurality of vectors comprising nucleic acid sequences corresponding to:
a) at least 6 internal genome segments from a donor virus other than A/Ann Arbor/6/60 and at least one genome segment encoding an immunogenic influenza surface antigen comprising the amino acid sequence of SEQ ID NO: 11; or
b) at least 6 internal genome segments from a donor virus other than A/Ann Arbor/6/60, wherein said donor virus has one or more phenotypic attributes selected from the group consisting of: attenuated, cold adapted and temperature sensitive; and at least one genome segment encoding an immunogenic influenza surface antigen comprising the amino acid sequence of SEQ ID NO: 11;
ii) culturing the population of host cells at a temperature less than or equal to 35° C.; and,
iii) recovering a plurality of influenza viruses.
27. An immunogenic composition comprising an immunologically effective amount of the influenza virus produced by the method comprising:
i) introducing into a population of host cells a plurality of vectors comprising nucleic acid sequences corresponding to:
a) at least 6 internal genome segments from a donor virus other than A/Ann Arbor/6/60 and a genome segment encoding an immunogenic influenza surface antigen comprising the amino acid sequence of SEQ ID NO: 11; or
b) at least 6 internal genome segments from a donor virus other than A/Ann Arbor/6/60, wherein said donor virus has one or more phenotypic attributes selected from the group consisting of: attenuated, cold adapted and temperature sensitive; and a genome segment encoding an immunogenic influenza surface antigen comprising the amino acid sequence of SEQ ID NO: 11;
ii) culturing the population of host cells at a temperature less than or equal to 35° C.; and,
iii) recovering a plurality of influenza viruses.
28. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the influenza virus produced by the method of claim 26 in a physiologically effective carrier.
29. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual the immunogenic composition of claim 27 .